Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer Ingelheim

Showing 15 posts of 109 posts found.

engelbert_tjeenk_willink_pv

Boehringer’s Engelbert Tjeenk Willink leaves firm

September 28, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Engelbert Tjeenk Willink

Boehringer Board member Engelbert Tjeenk Willink, responsible for Marketing and Sales of Prescription Medicines, has decided to leave at the …

Appointment

Trajenta added to insulin recommended in Europe

September 26, 2012
Sales and Marketing Boehringer Ingelheim, Trajenta, diabetes

The CHMP has recommended that Boehringer Ingelheim and Eli Liily and Co’s diabetes brand Trajenta should be approved as add-on …

News

Pharma creates non-profit R&D organisation

September 21, 2012
Research and Development, Sales and Marketing Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Pfizer, R&D, Roche Genentech, Sanofi, TransCelerate BioPharma, biopharma

Ten biopharma companies have formed TransCelerate BioPharma Inc, a not-for-profit organisation using money and personnel from each firm, with a …

News
Amanda Paxon image

Working Life: Amanda Paxon

August 9, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amanda Paxon, Boehringer Ingelheim, Working Life

 How did you find your way into your current role? Through a combination of good luck and hard work! I …

Feature

Boehringer wins contract to make Servier’s gevokizumab

August 7, 2012
Manufacturing and Production Boehringer Ingelheim, CMO, Servier, antibody

Boehringer Ingelheim’s contract manufacturing organisation (CMO) division will provide commercial-scale manufacturing of a new monoclonal antibody developed by Servier and …

News
joachim_hasenmaier

Boehringer Ingelheim makes changes to board

July 5, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim

Boehringer Ingelheim has appointed Dr Joachim Hasenmaier to its board of managing directors. The 52-year-old will take over responsibility for …

Appointment

Boehringer appoints new executive director of Consumer Healthcare Marketing

May 31, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim

Boehringer Ingelheim has announced the appointment of Ross Ullman as the executive director marketing of the Consumer Healthcare division.  In …

Appointment
Boehringer Ingelheim image

A family business: Pradaxa success lifts Boehringer

April 25, 2012
Research and Development, Sales and Marketing Boehringer Ingelheim

Rapid uptake of anti-clotting drug Pradaxa in the US has helped Boehringer Ingelheim enjoy a strong year, and looks set to …

Feature

Petition launched to raise AF and stroke awareness

April 20, 2012
Business Services, Medical Communications, Sales and Marketing AF, Boehringer Ingelheim, Pradaxa, Xarelto, stroke

Various health organisations have called on more people involved in the management of atrial fibrillation (AF) to help raise awareness …

News
Pradaxa image

NICE recommends Pradaxa for stroke prevention

March 15, 2012
Sales and Marketing Boehringer Ingelheim, NICE, Pradaxa, atrial fibrillation

NICE has given a limited recommendation to Boehringer Ingelheim’s blood thinner Pradaxa. The watchdog said in final guidance that Pradaxa …

News
Pradaxa image

Boehringer censured over Pradaxa website

March 8, 2012
Medical Communications ABPI, Boehringer Ingelheim, PMCPA, Pradaxa

Boehringer Ingelheim has breached the ABPI’s Code of Conduct over the use of its Pradaxa website.    Pradaxa is a …

News
Boehringer picture

Boehringer to invest €17m in Biberach, Vienna facilities

March 6, 2012
Manufacturing and Production Austria, BI-HEX, Boehringer Ingelheim, Vienna, manufacturing

Boehringer Ingelheim has said it plans to invest around €17 million in its biopharmaceutical development and manufacturing capabilities at Biberach, …

News
Boehringer picture

Boehringer broadens afatinib studies

January 27, 2012
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, afatinib

Boehringer Ingelheim is expanding the scope of its studies into afatinib to test its use against head and neck cancers. …

News
Boehringer pic

Boehringer invests $65 million in early R&D centre

November 16, 2011
Research and Development, Sales and Marketing Boehringer Ingelheim

Boehringer Ingelheim is investing $65 million for an early-stage research and development centre in the US. The new 72,000 sq.ft. …

News
Boehringer Facebook image

Boehringer developing Facebook game

November 15, 2011
Medical Communications Boehringer Ingelheim, Facebook

Boehringer Ingelheim is developing a new Facebook civilisation game in the hopes of helping the public understand the difficulty involved …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023